Anthony Hunt

Anthony Hunt (chief executive) discloses dealings in 3 companies, chiefly Repligen Corp, 908 Devices Inc. and Biolife Solutions Inc. The record holds 46 filings, for trades running from 19 May 2021 to 6 October 2026.

On the open market, the record shows 1 purchase worth €231k and 4 sales worth €1.2M. Netting one side against the other leaves €965k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 16 share grants and 19 option exercises.

On 8 October 2026 came the latest disclosure, a transaction in Biolife Solutions Inc. The most recent open-market purchase was published on 14 June 2024, 856 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.